Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. decreased its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 23.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,057 shares of the biopharmaceutical company’s stock after selling 2,749 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in Theravance Biopharma were worth $77,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its holdings in Theravance Biopharma by 68.0% during the fourth quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company’s stock valued at $3,227,000 after purchasing an additional 116,164 shares in the last quarter. Gerber LLC purchased a new position in Theravance Biopharma in the 4th quarter valued at about $112,000. China Universal Asset Management Co. Ltd. lifted its stake in Theravance Biopharma by 66.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,583 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 3,824 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Theravance Biopharma by 16.6% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,876 shares of the biopharmaceutical company’s stock worth $474,000 after buying an additional 7,509 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Theravance Biopharma by 30.7% during the 1st quarter. BNP Paribas Financial Markets now owns 33,458 shares of the biopharmaceutical company’s stock worth $300,000 after buying an additional 7,851 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Analyst Ratings Changes

TBPH has been the subject of several research reports. StockNews.com cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. Leerink Partnrs cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Leerink Partners lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $15.00 to $10.00 in a report on Tuesday, August 6th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a research report on Monday, September 16th. Finally, TD Cowen cut their price target on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $13.75.

Theravance Biopharma Stock Performance

NASDAQ:TBPH opened at $8.10 on Friday. Theravance Biopharma, Inc. has a 12-month low of $7.44 and a 12-month high of $11.71. The firm has a market cap of $393.93 million, a PE ratio of -9.42 and a beta of 0.25. The stock has a fifty day moving average price of $8.32 and a 200 day moving average price of $8.82.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. The company had revenue of $14.26 million for the quarter, compared to analyst estimates of $15.81 million. During the same period in the prior year, the firm posted ($0.28) earnings per share. Equities analysts forecast that Theravance Biopharma, Inc. will post -1.04 EPS for the current year.

Insider Buying and Selling

In other Theravance Biopharma news, major shareholder Eli Samaha acquired 999,800 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were bought at an average cost of $7.80 per share, for a total transaction of $7,798,440.00. Following the completion of the purchase, the insider now owns 9,511,150 shares in the company, valued at $74,186,970. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, major shareholder Eli Samaha bought 999,800 shares of the stock in a transaction on Wednesday, August 7th. The shares were bought at an average cost of $7.80 per share, for a total transaction of $7,798,440.00. Following the purchase, the insider now owns 9,511,150 shares of the company’s stock, valued at $74,186,970. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now owns 335,965 shares of the company’s stock, valued at $3,023,685. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 6.90% of the stock is owned by company insiders.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.